Cellectar Biosciences Inc (CLRB) Actualités

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and...

Form 8-K - Current report

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data...

Form 8-K - Current report

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]